FEM
BNTX icon

Fulcrum Equity Management’s BioNTech BNTX Stock Holding History

Fulcrum Equity Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-823
Closed -$212K – 114
2021
Q4 		$212K Sell
823
-65
-7% -$17.8K 0.08% 166
2021
Q3 		$242K Buy
+888
New +$282K 0.09% 153

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fulcrum Equity Management's BNTX Position: Q1 2022 in Review

Fulcrum Equity Management sold out of BioNTech (BNTX) in Q1 2022, closing a stake of 823 shares — an estimated $212K sold.

Fulcrum Equity Management first reported a position in BNTX in Q3 2021 and held it in 2 quarters. The position peaked at $242K in Q3 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2022.

  • Fulcrum Equity Management reported no remaining BioNTech position as of Q1 2022 after selling out during the quarter.
  • Fulcrum Equity Management sold 823 BioNTech shares in Q1 2022, an estimated $212K.
  • Fulcrum Equity Management first reported a position in BioNTech in Q3 2021 and held it in 2 quarters.
  • Fulcrum Equity Management's BioNTech position peaked at $242K in Q3 2021.
  • 287 funds tracked by Wall St. Rank held BioNTech as of Q1 2022.

Based on Fulcrum Equity Management's 13F filing for Q1 2022, filed 15 Apr 2022.